Brief: Intercept Presents New Data Showing Significant Impact Of Oca-Bezafibrate Combination On Normalization Of Multiple Biomarkers Of Pbc-Induced Liver Damage
23/06/2023 07:47
June 23 (Reuters) - Intercept Pharmaceuticals Inc
ICPT.O :
* INTERCEPT PRESENTS NEW DATA SHOWING SIGNIFICANT IMPACT OF
OCA-BEZAFIBRATE COMBINATION ON NORMALIZATION OF MULTIPLE
BIOMARKERS OF PBC-INDUCED LIVER DAMAGE
* INTERCEPT PHARMACEUTICALS INC SAYS COMBINATION
WELL-TOLERATED
WITH LOWEST RATES OF PRURITUS OBSERVED IN OCA 5-10 MG +
BEZAFIBRATE 400 MG TREATMENT ARM
Source text for Eikon: ID:nGNX7s1m7f
Further company coverage: ICPT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Intercept Pharmaceuticals
See all newsIntercept Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Digitalbridge Group, Huntington Ingalls Industries, Workday
U.S. RESEARCH ROUNDUP-Docusign, Immunovant, Liberty Energy
U.S. STOCKS ON THE MOVE-Amazon, United Parcel Service, Nike
U.S. STOCKS ON THE MOVE-BullFrog AI, Soleno,